Research Advances in the Mutation of TET2 Gene in Myeloid Maligancies.
10.3881/j.issn.1000-503X.2016.05.017
- Author:
Rong LI
1
;
Ming-Jiang XU
1
;
Feng-Chun YANG
1
;
Yuan ZHOU
1
Author Information
1. State Key Laboratory of Experimental Hematology,Institute of Hematology and Blood Disease Hospital,CAMS and PUMC,Tianjin 300020,China.
- Publication Type:Journal Article
- MeSH:
5-Methylcytosine;
analogs & derivatives;
metabolism;
DNA-Binding Proteins;
genetics;
Hematologic Neoplasms;
genetics;
Humans;
Mutation;
Proto-Oncogene Proteins;
genetics
- From:
Acta Academiae Medicinae Sinicae
2016;38(5):583-588
- CountryChina
- Language:English
-
Abstract:
TET2 gene is a member of TET oncogene family. It has been reported as a tumor suppressor gene with important roles in myelopiesis. Recent studies have shown that TET2 protein takes part in demethylation by converting 5-methylcytosine (5-mc) into 5-hydroxymethylcytosine (5-hmc). Somatic TET2 inactivation leads to abnormal myelopiesis and myeloid malignancies. In this review,the structure and function of TET2 and the relationship between TET gene mutation and myeloid malignancies are summarized.
